5 minutes with Associate Professor Georgina Long

5 minutes with Associate Professor Georgina Long

17 December 2015

What research projects and trials are you currently working on?

There are many research projects and clinical trials that I am working on, most of which are collaborations across MIA, or collaborations with national and international colleagues. The projects cover a range of areas, including: the genetic characteristics of melanoma itself; why melanoma responds or becomes resistant to drug therapies (and we have projects looking at combined targeted therapies and combined immunotherapies); and projects as to why some people’s genetics might predispose them to certain side-effects with drug therapies. 

We are working on numerous clinical trials many are MIA home-grown trials, including the neoadjuvant study of targeted therapy for bulky stage III BRAF-mutant melanoma. This study has a dual purpose: 1) to see if we can shrink the melanoma to become more easily resectable by the surgeons; and 2) whether we can give a course of drug therapy to prevent melanoma spreading to distant sites like the liver, lung and brain. 

We are also in the midst of writing a protocol for a similar neoadjuvant approach, however using combined immunotherapy and targeted therapy. We have recruited more than half the number of patients required for the Australian Brain Collaboration, which is exploring combined nivolumab and ipilimumab versus nivolumab alone in active brain metastases. 

In 2016 we will be opening trials of new combinations of immunotherapies for patients with metastatic melanoma. We are recruiting very well to an adjuvant study for stage III melanoma of pembrolizumab versus placebo because at the moment, the standard of care for stage III is observation with close monitoring. This gives you an idea of some of the projects, but I’ve really only touched on 10% of all the work we are doing. We have recently submitted the first results from our Genome Project to be reviewed for publication, and these results have very important implications for patients with acral or mucosal melanoma.

You presented world first research at the biggest melanoma conference in the world recently. Tell us about this research? 

I presented some exciting results from several international phase 1 clinical trials that we have conducted here at MIA. The first was a phase 1 (first in humans) study of pembrolizumab, an anti-PD-1 antibody, combined with ipilimumab, an anti-CTLA-4 antibody. I reported on the first efficacy results and toxicities. It was well tolerated using a smaller dose of ipilimumab, and only 17% of patients developed a grade 3-4 immune related adverse event. The response rate, meaning those that had a deep response in their melanoma, was 56% which is similar to what has been reported in a large study of nivolumab, another anti-PD-1 drug, combined with ipilimumab, however with ipilimumab at a full dose.

The second study I presented was another world-first phase 1 study (first in humans) of the oncolytic virus T-VEC with pembrolizumab. This had a response rate of 56%; however this was only in 16 evaluable patients, so very small numbers. The combination was very well tolerated with no new side effects, but similar side effects to what you may see with each drug alone. 
Another study I presented was a pooled analysis of over 600 patients who had received combined targeted therapy, a BRAF and MEK inhibitor (dabrafenib and trametinib), for BRAF-mutant melanoma across several randomised trials in stage IV. Interestingly, the greatest predictor of overall survival was the patient’s level of LDH before they started the drug. LDH is a protein that we produce when our normal cells turnover, however may rise above normal levels if the melanoma is particularly aggressive. 

What are your goals for research in the future?

I have a very simple goal and that is to prevent and cure melanoma and hope that the results we see in melanoma can be used in other cancers.

What drives you to work so hard and achieve such amazing results?

My drive is doing something positive for the human race. Although I love doing things for individuals and I am driven by the patients I see in clinic, the greatest thing is to think that you may be impacting thousands of people, not only those with melanoma, but people with other cancers. It is hard work to conduct so many clinical trials: it’s not easy, it requires a lot of effort, expertise and teamwork, but it’s worth it when you see the results we have seen in the last 3-4 years. And we believe we are curing some people with metastatic or stage IV melanoma.

How will you celebrate Christmas this year?

I will be celebrating Christmas with my family. If it wasn’t for my family and their support, there is no way I could do what I do. My husband is an amazing support for me and the work I do. In fact, the results I see from the work I do with my colleagues at MIA, I really have to say are the result of his hard work as well. 

To fund leading melanoma research, you can make a donation here. 

 

 

A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma
Professor Georgina Long hands on baton of SMR Presidency
31 Oct 2020

Professor Georgina Long hands on baton of SMR Presidency

Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

Tags: melanoma
City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts at MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma